Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Telisotuzumab vedotin (Emrelis) for non-small cell lung cancer.
Journal: The Medical letter on drugs and therapeutics
Published: July 29, 2025
Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC).
Journal: Drug discoveries & therapeutics
Published: July 13, 2025
Assessment of Telisotuzumab Vedotin Drug-Drug Interaction Potential Using Physiologically-Based Pharmacokinetic Modeling and Simulations.
Journal: Journal of clinical pharmacology
Published: June 18, 2025
Evolving roles of MET as a therapeutic target in NSCLC and beyond.
Journal: Nature reviews. Clinical oncology
Published: June 12, 2025
Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer.
Journal: Genes
Published: June 03, 2025
Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.
Journal: Chembiochem : a European journal of chemical biology
Published: April 11, 2025
Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials.
Journal: Pharmaceutics
Published: March 25, 2025
Telisotuzumab vedotin and osimertinib: the METamorphosis of epidermal growth factor receptor-mutant lung cancer?
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 13, 2025
Recent advances in therapeutic strategies for non-small cell lung cancer.
Journal: Journal of hematology & oncology
Published: November 18, 2024
Last Updated: 10/31/2025